Objectives. T cells play an essential role in controlling the development of B-cell lymphoproliferative disorders (BLPDs) 
INTRODUCTION
B-cell lymphoproliferative disorders (BLPDs) are a collection of lymphoid malignancies that are characterised by the abnormal accumulation of B lymphocytes in bone marrow and peripheral lymphoid tissues. 1 Animal models have convincingly demonstrated that T cells can recognise and eliminate malignant B cells to prevent the development of BLPDs, 2 suggesting that the dysfunction of the immune system could be a major risk factor for BLPDs. In line with the observation in mouse models, several studies reported altered T-cell composition and function in BLPD patients. [3] [4] [5] [6] [7] [8] [9] Although results from human studies were not always consistent and sometimes contradictory, probably due to distinct BLPD types and different criteria for patient recruitment, most studies suggested a breakdown of immune surveillance in BLPDs, demonstrated by excessive regulatory T (Treg) cells [3] [4] [5] and the dysfunctional phenotype of CD8 + T cells towards exhaustion [6] [7] [8] [9] in patients. Such findings provided rationales for the application of T-cell immune signature in the discovery of prognostic markers and the development of targeted immunotherapies. However, it remains challenging to know which types of BLPDs, within such a diversified collection, are more prone to immune dysregulation, and, consequently, should be given a priority for further investigation.
Here, we systematically characterised the composition of all major functional subsets of CD4 + helper T cells (Th) and CD8 + cytotoxic T cells (Tc) in non-Hodgkin lymphoma (NHL) BLPD patients. The cohort was composed of both indolent and aggressive categories with various subtypes. We identified indolent but not aggressive BLPDs showing a prominent T-cell immune signature of the excessive generation of type I helper T (Th1) cells and follicular helper T (Tfh) cells, and the hyperactivation of cytotoxic T cells that are likely driven towards exhaustion by the expression of PD-1. Therefore, these Tcell immune signatures represent prior candidates for biomarker discovery and target immunotherapy development, especially in indolent BLPDs.
RESULTS

T-cell signatures are primarily associated with indolent BLPDs
Treatment-na€ ıve patients with BLPDs (nonHodgkin's lymphomas, n = 94) were recruited and clinically categorised as indolent (n = 75) or aggressive (n = 19 Patients with indolent BLPDs were significantly older than those with aggressive BLPDs (median age: 56 vs. 47 years old, P = 0.0066). As a result, a single healthy control group was unable to match the ages for both patient groups. We, therefore, recruited healthy subjects (25-50 years old, n = 66) since the immune system from middleaged adults is regarded as the representative for a normal state.
T-cell function was analysed using flow cytometry to measure all major subsets of CD4 14 We observed a striking upregulation of the frequencies of Tfhem cells in indolent BLPDs, as compared to aggressive BLPDs and HCs (Figure 1b) , suggesting that the aberrant Tfh cell-mediated help might be a common mechanism underlying the survival and proliferation of indolent BLPDs. Another Th functional subset, CXCR3 
T-cell signatures stratify BLPDs
Since T-cell immune signatures were found particularly associated with indolent BLPDs, we then hypothesised that certain T-cell signatures might selectively mark indolent BLPDs. We first adopted principal component analysis (PCA) using all 15 T-cell immune signatures generated by flow cytometry, but it was insufficient to efficiently separate aggressive vs. indolent groups (Supplementary figure 5a) . The result could be explained by the heterogeneity for both indolent and aggressive groups which are composed of several subsets. The complexity might be further compounded by the fact that some signatures with marginal power for distinction could interfere with the clustering. Nevertheless, PC1 appeared to provide a better distinction than PC2 (Supplementary figure 5a) , suggesting appreciable Based on the promise, we then took a nonhypothesis-driven approach by applying a machine learning algorithm -random forest modelling to rank T-cell immune signatures. This is a computationally extensive and robust datamining algorithm that accommodates a large set of variables to identify the most associated factors using an ensemble of classifications trees. 19 Figure 2c ). Such binary classification generated by machine learning matched the clinical classifications for > 85% (65/75) indolent BLPDs but demonstrated little discriminative power for aggressive BLPDs, echoing the conclusion drawn from the comparative analysis between indolent and aggressive groups that dysregulated T-cell signatures were predominantly identified in indolent but not aggressive BLPDs (Figure 1 ).
T-cell signatures predict chemotherapy response and survival in indolent BLPDs
Since T-cell immune signatures were specifically associated with indolent BLPDs, we next investigated the relationship between T-cell signatures and disease prognosis in indolent BLPDs. Using the top four variables identified by random forest modelling (Figure 2a) , 75 indolent BLPD patients were clustered into two groups (Figures 3a and b) . Patients in one group displayed a more prominent immune signature of T cells (T-cell Signature Prominent, n = 27) including significantly lower frequencies of Thna€ ıve cells and higher frequencies of Th1, Tfhem and Tc exhaustion-like cells than these variables of patients in the other group (T-cell Signature Modest, n = 48) (Figure 3c) . By comparing the clinical data between two groups (Table 1) , we found patients with prominent T-cell signatures (T-cell Signature Prominent group) demonstrated worse prognosis than those with modest T-cell signatures (T-cell Signature Modest group), indicated by reduced 3-year progression-free survival (PFS) rates (61.4 AE 11.4% vs. 94.7 AE 3.7%, P = 0.043) (Figure 3d ). Consistent with reduced PFS rates, the rate of elevated serum lactate dehydrogenase (LDH) (80.0% vs. 40.0%, P = 0.032) and the deletion of 17p (18.2% vs. 5.1%, P = 0.100), usually associated with poorer prognosis, were higher in the T-cell Signature Prominent group than in the T-cell Signature Modest group. In addition, patients in the T-cell Signature Prominent group showed a lower response rate to immuno-chemotherapies than the T-cell Signature Modest group (CR rate 23.8% vs. 50.0%, P = 0.035, Table 1 ).
DISCUSSION
The dysregulation of T-cell function was reported in individual subtypes of BLPDs, but the overall picture has not been depicted. Our which can gradually acquire the state of exhaustion by the chronic stimulation of malignant B cells. 18 Furthermore, since IFN-c produced by Th1 cells can upregulate PD-L1 expression on tumour cells, 16 it is conceivable that the excessive Th1 differentiation may also render the risk of CD8 + T-cell exhaustion through the PD-1-PD-L1 interactions. Treg cells were found upregulated in indolent compared to aggressive BLPDs, indicating a greater immune suppression in indolent BLPDs, which might cripple the effector differentiation and killing function of Tc cells.
Therefore, the development of indolent BLPDs was accompanied by an immune environment not only promoting B-cell growth by increased Tfh function but also impairing immune surveillance due to enhanced Treg-mediated immune suppression and exhaustion-associated dysfunction of Tc cells (Supplementary figure 6) . Notably, the dysregulated T-cell immune signatures associated with indolent BLPDs were more prominent in a subgroup (T-cell Signature Prominent) that showed special tumour characteristics and poor prognosis. Patients in this T- cell Signature Prominent subgroup, compared to the other subgroup with modest signature of T-cell dysregulation (T-cell Signature Modest), demonstrated elevated LDH which indicates high tumour load and the higher frequencies of del17p which serves as a crucial genetic marker for aggressive behaviour of tumour cells. 20 It is difficult to distinguish whether the stronger dysregulation of T-cell immunity was the cause or the consequence of the features for malignancy although the worse prognosis in the T-cell Signature Prominent subgroup suggests the impaired immune surveillance may lead to the progress of indolent BLPDs. One way to examine this notion is to test whether the reinstatement of normal T-cell function can benefit the treatment of indolent BLPDs. Lenalidomide is an approved therapy with immunomodulatory functions. It was reported to improve the impaired T-cell immune synapse in FL 21 and CLL, 6 to enhance the activation of CD8 + T and NK cells, and to reduce Treg cells and rebalance Th subsets. 22 The BTK inhibitor ibrutinib is another candidate to help the immune normalisation, which was recently demonstrated to improve the function of T cells including modulating Th1/Th2 subsets. 23 Future studies are required to examine whether patients with superior responses to lenalidomide, ibrutinib or other immunomodulatory drugs demonstrate better improvement of T-cell immunity. Complementary approach is to utilise mouse models to test whether the prone differentiation to Tc exhaustion or the excessive help of Tfh cells can promote the development of BLPDs.
Our observations also shed light on the application of immunotherapies for BLPDs. For example, immune checkpoint inhibition has been trialled as a new therapy for BLPDs. Although > 60% objective response rates (ORRs) were recorded for PD-1 blockade in Hodgkin lymphoma, clinical outcomes with PD-1 blockade in BLPDs (non-Hodgkin's lymphoma) have been disappointing, with ORRs as~10% or less. 24 The results from our study suggest indolent BLPDs might be more suitable for PD-1 blockage therapy, particularly those with prominent signatures for dysregulated T-cell immunity including the exhaustion of Tc cells. Nevertheless, multiple defects of T-cell function revealed by our 
METHODS
Patient samples
Treatment-na€ ıve patients of BLPD (non-Hodgkin's lymphoma) aged from 15 to 81 (n = 94) were enrolled into this study. The diagnosis was according to the 4th edition of World Health Organization Classification. 1 At the time of sampling, patients diagnosed with infection or autoimmune diseases were excluded from this study. Peripheral blood samples were collected in Blood Diseases Hospital, Tianjin, China. Written informed consents were signed in accordance with the requirements of the Declaration of Helsinki. Blood samples from healthy individuals aged from 25 to 50 (n = 66) were collected as controls. The Ethics Committee of Blood Disease Hospital (NI2016001-EC-1) approved this study. The peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque (GE Healthcare Bio-sciences AB, Uppsala, Sweden), resuspended in 10% DMSO (Sigma Aldrich, Saint Louis, MO, USA) and 90% foetal bovine serum (FBS; Gibco, Waltham, MA, USA) and stored at À80°C until use. All the clinical data were collected at diagnosis.
Flow cytometric analysis for immune phenotyping
Peripheral blood mononuclear cells were thawed in warm media, washed twice and resuspended at 1 9 10 7 viable cells per mL. About 50-100 lL cells per well were stained for 45 min at room temperature with antibodies listed in Supplementary table 2. Cells were washed three times with FACS buffer (PBS supplemented with 2% FBS and 0.1% EDTA) and resuspended in 200 lL FACS buffer. A total of 100 000 lymphocytes per sample were collected using DIVA 6.0 software on a FACS Aria III Cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data analysis was performed using FlowJo v9 software (Tree Star, Inc., Ashland, OR, USA). The detailed gating strategy for T-cell subsets is outlined in Supplementary figure 1. 
